The market already knew the direction was improving, but not this magnitude. Flotek had raised 2026 targets on August 4, so another increase was partly anticipated; the new information is the roughly 6% lift in both guidance midpoints. The filing moves revenue to $360M-$370M from $340M-$350M and Adjusted EBITDA to $50M-$54M from $47M-$51M (FY 2026 updated guidance). 〔0〕
| Metric | Previous guidance | New guidance | Midpoint change |
|---|---|---|---|
| 2026 revenue | $340M-$350M | $360M-$370M | $345M to $365M |
| 2026 Adjusted EBITDA | $47M-$51M | $50M-$54M | $49M to $52M |
| Midpoint growth vs. 2025 | — | — | Revenue +54%; Adjusted EBITDA +58% |
The upgrade is being driven primarily by international chemistry, not a broad-based reset. Second-quarter international chemistry revenue reached $10.6M, and management now expects more than $40M during the second half, supported by ongoing Saudi Arabia work. That makes the forecast more dependent on execution, logistics, and geopolitical conditions in the region than the prior outlook.
The operating leverage signal is credible but remains partly non-GAAP. The company projects 2026 Adjusted EBITDA of $50M-$54M versus $32.79M in 2025, while noting that the forecast excludes roughly $9M of non-cash contract-asset amortization and cannot be reconciled to GAAP net income without unreasonable effort (Adjusted EBITDA reconciliation).
Net read: a genuine guidance beat versus the standing company outlook, with execution risk moving to the center of the story. The second raise materially improves the near-term earnings framework, but the incremental upside rests heavily on converting Saudi-related international chemistry demand into more than $40M of second-half revenue.
Read the original 8-K on SEC EDGAR ↗